Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Study of Sacituzumab Tirumotecan (SKB264) Combined With Brain Radiotherapy in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer With Brain Metastasis After Progression on First-Line Third-Generation EGFR-Tyrosine Kinase Inhibitors

NCT07789444 is registered in ClinicalTrials.gov with Xiaorong Dong as lead sponsor.

NCT NCT07789444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Study of Sacituzumab Tirumotecan (SKB264) Combined With Brain Radiotherapy in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer With Brain Metastasis After Progression on First-Line Third-Generation EGFR-Tyrosine Kinase Inhibitors
Lead sponsor
Xiaorong Dong
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 30, 2026
Completion date
December 1, 2028
Enrollment
53 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases from non-small cell lung cancer (nsclc), egfr mutation positive advanced non-small cell lung cancer, non-small cell lung cancer